Get the Stockscreener App
0.27
0.74%
-0.002
After Hours:
.27
Processa Pharmaceuticals Inc stock is traded at $0.27, with a volume of 604.58K.
It is down -0.74% in the last 24 hours and down -17.18% over the past month.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
See More
Previous Close:
$0.272
Open:
$0.2757
24h Volume:
604.58K
Relative Volume:
0.07
Market Cap:
$15.29M
Revenue:
-
Net Income/Loss:
$-12.88M
P/E Ratio:
-0.1163
EPS:
-2.3215
Net Cash Flow:
$-10.85M
1W Performance:
-2.88%
1M Performance:
-17.18%
6M Performance:
-21.58%
1Y Performance:
-78.40%
1-Day Range:
$0.26
$0.28
1-Week Range:
$0.257
$0.3049
52-Week Range:
$0.15
$1.22
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Name
Processa Pharmaceuticals Inc
Sector
Industry
Phone
443-776-3133
Address
601 21ST STREET, SUITE 300, VERO BEACH
Compare PCSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
0.27 | 15.41M | 0 | -12.88M | -10.85M | -2.3215 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-24 | Initiated | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Stock (PCSA) Latest News
Processa Pharmaceuticals Inc (PCSA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Processa Pharmaceuticals (PCSA) Stock Analysis Report | Financials & Insights - Benzinga
Will Processa Pharmaceuticals Inc. stock attract more institutional investorsWeekly Investment Report & Weekly Stock Performance Updates - Newser
How Processa Pharmaceuticals Inc. stock performs in weak economyPortfolio Performance Summary & Fast Entry High Yield Tips - Newser
The time has not yet come to remove your chips from the table: Processa Pharmaceuticals Inc (PCSA) - Setenews
Will Processa Pharmaceuticals Inc. stock outperform Dow Jones indexMarket Sentiment Report & Verified Swing Trading Watchlist - Newser
Processa Pharmaceuticals faces Nasdaq delisting risk over share price - MSN
How Processa Pharmaceuticals Inc. stock reacts to oil pricesPortfolio Profit Report & Intraday High Probability Alerts - BỘ NỘI VỤ
Financial Contrast: Plus Therapeutics (NASDAQ:PSTV) & Heatwurx (NASDAQ:PCSA) - Defense World
Processa Pharmaceuticals Inc (PCSA) looking to reclaim success with recent performance - setenews.com
What analysts say about Processa Pharmaceuticals Inc stockRelative Strength Index (RSI) & Crush the Market with Breakout Winners - earlytimes.in
Processa Pharmaceuticals Inc. stock prediction for this week2025 Volume Leaders & Long-Term Growth Stock Strategies - newser.com
Can trapped investors hope for a rebound in Processa Pharmaceuticals Inc.Quarterly Risk Review & Free Real-Time Market Sentiment Alerts - newser.com
Will Processa Pharmaceuticals Inc. stock remain a Wall Street favoriteEarnings Performance Report & Risk Controlled Swing Alerts - newser.com
Will Processa Pharmaceuticals Inc. stock split again soon2025 Technical Overview & Safe Capital Growth Tips - newser.com
Is Processa Pharmaceuticals Inc. stock ready for a breakoutWeekly Loss Report & Weekly Breakout Stock Alerts - newser.com
Will Processa Pharmaceuticals Inc. stock benefit from infrastructure spendingMarket Activity Report & Technical Confirmation Trade Alerts - newser.com
Applying Wyckoff theory to Processa Pharmaceuticals Inc. stockJuly 2025 Snapshot & Daily Entry Point Alerts - newser.com
Can you recover from losses in Processa Pharmaceuticals Inc.Earnings Trend Report & Long-Term Growth Portfolio Plans - newser.com
Can Processa Pharmaceuticals Inc. recover in the next quarterLayoff News & Accurate Intraday Trading Signals - newser.com
Pattern recognition hints at Processa Pharmaceuticals Inc. upsideM&A Rumor & AI Forecasted Stock Moves - newser.com
What AI ML Trends Might Elevate Gland Pharma Limited’s Stock ProspectsMarket Sentiment Surveys & Get Alerts Before Market Turns Ugly - earlytimes.in
Ready to Jump After Recent Trade: Processa Pharmaceuticals Inc (PCSA) - Setenews
Trend analysis for Processa Pharmaceuticals Inc. this week - newser.com
How to read the order book for Processa Pharmaceuticals Inc.July 2025 Trade Ideas & AI Based Buy and Sell Signals - newser.com
Is Processa Pharmaceuticals Inc. meeting your algorithmic filter criteriaTrade Risk Summary & Daily Technical Forecast Reports - newser.com
Is Processa Pharmaceuticals Inc. stock trading near support levels2025 Top Decliners & Safe Capital Growth Trade Ideas - newser.com
Retail Trends: Can Processa Pharmaceuticals Inc. stock outperform in 2025 bull marketRate Cut & Free Safe Capital Growth Stock Tips - Fundação Cultural do Pará
Using data filters to optimize entry into Processa Pharmaceuticals Inc.July 2025 Levels & Real-Time Chart Breakout Alerts - newser.com
Processa Pharmaceuticals Inc Stock (PCSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):